CL2015000608A1 - Formulaciones de daptomicina y usos de la misma - Google Patents

Formulaciones de daptomicina y usos de la misma

Info

Publication number
CL2015000608A1
CL2015000608A1 CL2015000608A CL2015000608A CL2015000608A1 CL 2015000608 A1 CL2015000608 A1 CL 2015000608A1 CL 2015000608 A CL2015000608 A CL 2015000608A CL 2015000608 A CL2015000608 A CL 2015000608A CL 2015000608 A1 CL2015000608 A1 CL 2015000608A1
Authority
CL
Chile
Prior art keywords
formulation
salts
daptomycin formulations
daptomycin
formulations
Prior art date
Application number
CL2015000608A
Other languages
English (en)
Inventor
Jim Alexiou
Andrew Knill
Noel Norris
Darryl Whittaker
Original Assignee
Hospira Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50277707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015000608(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hospira Australia Pty Ltd filed Critical Hospira Australia Pty Ltd
Publication of CL2015000608A1 publication Critical patent/CL2015000608A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

FORMULACION DE DAPTOMICINA LIOFILIZADA QUE COMPRENDE UN ADITIVO SELECCIONADO DE ANTIOXIDANTES, ACIDOS ORGANICOS Y SUS SALES, DERIVADOS DE GLUOCSA Y SUS SALES Y COMBINACIONES DE LOS MISMOS; METODO PARA PREPARARLA; METODO DE TRATAMIENTO O PREVENCION DE UNA BIOLAMINA; Y USO DE LA FORMULACION PARA TRATAR UNA INFECCION BACTERIANA.
CL2015000608A 2012-09-11 2015-03-11 Formulaciones de daptomicina y usos de la misma CL2015000608A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261699570P 2012-09-11 2012-09-11
US201361839699P 2013-06-26 2013-06-26

Publications (1)

Publication Number Publication Date
CL2015000608A1 true CL2015000608A1 (es) 2015-11-06

Family

ID=50277707

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015000608A CL2015000608A1 (es) 2012-09-11 2015-03-11 Formulaciones de daptomicina y usos de la misma

Country Status (20)

Country Link
US (4) US9655946B2 (es)
EP (2) EP4066849A1 (es)
AU (2) AU2013316779A1 (es)
BR (1) BR112015005400B1 (es)
CA (1) CA2884484C (es)
CL (1) CL2015000608A1 (es)
CY (1) CY2200004T2 (es)
DE (1) DE13837694T1 (es)
DK (1) DK2895187T1 (es)
ES (1) ES2552754T1 (es)
HK (1) HK1207006A1 (es)
HU (1) HUE13837694T1 (es)
IL (1) IL237652B (es)
MX (1) MX366122B (es)
NZ (3) NZ706286A (es)
SA (1) SA515360129B1 (es)
SG (1) SG11201506113WA (es)
TN (1) TN2015000090A1 (es)
WO (1) WO2014041425A1 (es)
ZA (1) ZA201502310B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2552754T1 (es) * 2012-09-11 2015-12-02 Hospira Australia Pty Ltd Formulaciones de daptomicina y usos de la misma
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
US10933019B2 (en) 2016-10-21 2021-03-02 Xellia Pharmaceuticals Aps Liquid formulations of daptomycin
MX2020001885A (es) * 2017-08-31 2020-09-07 Xellia Pharmaceuticals Aps Formulaciones de daptomicina.
CN110339342A (zh) * 2018-04-03 2019-10-18 江苏恒瑞医药股份有限公司 一种达托霉素的盐或含盐的组合物及其制备方法
US11058745B1 (en) 2018-10-04 2021-07-13 Good Health, Llc Stable liquid pharmaceutical compositions of daptomycin
AU2021215396A1 (en) 2020-02-03 2022-09-29 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases
CA3170514A1 (en) 2020-03-12 2021-09-16 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol
IL300090A (en) 2020-07-24 2023-03-01 Genzyme Corp Pharmaceutical preparations containing VENGLUSTAT
CN115590825B (zh) * 2022-10-20 2024-02-02 安士制药（中山）有限公司 一种注射用达托霉素及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5560906A (en) * 1995-03-27 1996-10-01 Oral Technology Laboratories, Inc. Non-alcoholic antimicrobial mouthwash for removal of dental plaque
PL206091B1 (pl) * 1998-09-25 2010-06-30 Cubist Pharmaceuticals Zastosowania daptomycyny
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
WO2002059145A1 (en) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
CN1616083A (zh) * 2004-09-01 2005-05-18 魏雪纹 注射用达托霉素冻干制剂及制备方法
WO2006130629A2 (en) * 2005-05-31 2006-12-07 Cubist Pharmaceuticals, Inc. Daptomycin for the treatment of biofilm and catheter salvage
FI2504353T4 (fi) 2009-11-23 2023-11-30 Cubist Pharmaceuticals Llc Lipopeptidikoostumukset ja vastaavat menetelmät
US20110124551A1 (en) * 2009-11-23 2011-05-26 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
BR112015003198A2 (pt) * 2012-08-23 2017-10-10 Mylan Laboratories Ltd formulação injetável de daptomicina melhorada.
ES2552754T1 (es) * 2012-09-11 2015-12-02 Hospira Australia Pty Ltd Formulaciones de daptomicina y usos de la misma

Also Published As

Publication number Publication date
BR112015005400A2 (pt) 2017-07-04
DE13837694T1 (de) 2015-12-31
AU2018217322B2 (en) 2020-08-27
EP4066849A1 (en) 2022-10-05
ZA201502310B (en) 2019-09-25
EP2895187A4 (en) 2015-12-02
US9655946B2 (en) 2017-05-23
US20150313958A1 (en) 2015-11-05
MX366122B (es) 2019-06-27
NZ741342A (en) 2019-10-25
IL237652B (en) 2020-06-30
DK2895187T1 (da) 2015-11-16
AU2013316779A1 (en) 2015-04-02
US10357535B2 (en) 2019-07-23
CA2884484A1 (en) 2014-03-20
EP2895187A1 (en) 2015-07-22
US20180177843A1 (en) 2018-06-28
AU2018217322A1 (en) 2018-09-06
WO2014041425A1 (en) 2014-03-20
NZ742241A (en) 2019-08-30
HUE13837694T1 (hu) 2016-04-28
TN2015000090A1 (en) 2016-06-29
SG11201506113WA (en) 2015-09-29
IL237652A0 (en) 2015-04-30
MX2015003164A (es) 2015-12-16
CA2884484C (en) 2021-01-19
US20200237858A1 (en) 2020-07-30
SA515360129B1 (ar) 2016-08-15
NZ706286A (en) 2018-05-25
ES2552754T1 (es) 2015-12-02
CY2200004T2 (el) 2016-02-10
HK1207006A1 (en) 2016-01-22
US20170216396A1 (en) 2017-08-03
BR112015005400B1 (pt) 2022-03-08

Similar Documents

Publication Publication Date Title
CL2015000608A1 (es) Formulaciones de daptomicina y usos de la misma
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
CO2017001994A2 (es) Compuestos activos hacia bromodominios
GT201600183A (es) Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas
MA39727A (fr) Compositions antimicrobiennes pour végétaux
CL2017003151A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
CL2016003398A1 (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo.
UY36342A (es) Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos
CO7091182A2 (es) Inhibidores de beta-lactamasa isoxazol
BR112017001796A2 (pt) composições de flagelina e seus usos
CR20150462A (es) Inhibidores de erk y sus usos
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
BR112017028038A2 (pt) composições antimicrobianas e usos das mesmas
CL2017000576A1 (es) Inhibidores de mk2 y sus usos
CU20170089A7 (es) Derivados de quinazolina utilizados para tratar el vih
CL2016000313A1 (es) Compuestos de benzoxaborol tricíclicos y usos de los mismos
UY35274A (es) Compuestos y métodos para tratar infecciones bacterianas
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
CL2015001772A1 (es) Composición farmacéutica para el tratamiento de dolor cabeza, y método de preparación de la misma.
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
BR112017023432A2 (pt) Derivados de ácido propiônico tetra- hidronaftiridinila e usos do mesmo
CO7250444A2 (es) Uso de seaprose para eliminar biopelículas bacterianas
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.